The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer.
digital PCR
early recurrence
genetic testing
liquid biopsy
triple-negative breast cancer
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
26
03
2020
accepted:
16
09
2020
entrez:
12
4
2021
pubmed:
13
4
2021
medline:
13
4
2021
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC) has a poorer prognosis than other breast cancer subtypes; therefore, identifying markers of early recurrence is important. The present study aimed to establish a liquid biopsy protocol for droplet digital PCR-based detection of frequently mutated genes in patients with TNBC. Tumor DNA from 36 patients with TNBC who relapsed within 2 years after surgical resection was retrospectively analyzed. Somatic mutational profiles were evaluated using targeted sequencing to identify frequently mutated genes and genes associated with molecularly targeted therapies. The association between genetic alterations and associated protein phosphorylation was investigated using immunohistochemical analysis. Recurrent hot spot mutations in the plasma were monitored over time. Mutation-specific probes were used to successfully detect mutations in the blood samples of patients who were positive for
Identifiants
pubmed: 33841581
doi: 10.3892/ol.2021.12681
pii: OL-0-0-12681
pmc: PMC8020385
doi:
Types de publication
Journal Article
Langues
eng
Pagination
420Informations de copyright
Copyright © 2021, Spandidos Publications.
Déclaration de conflit d'intérêts
YMiz and YOn receive funding from Hitachi High Technologies, Inc. for the experimental equipment. No potential conflicts of interest were disclosed by the other authors.
Références
Br J Cancer. 2008 May 6;98(9):1533-5
pubmed: 18392055
Oncoimmunology. 2016 Mar 30;5(6):e1169356
pubmed: 27471649
Nat Rev Cancer. 2011 Jun;11(6):426-37
pubmed: 21562580
J Clin Oncol. 2004 Jul 15;22(14):2849-55
pubmed: 15254052
Mol Oncol. 2017 Oct;11(10):1448-1458
pubmed: 28691390
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
J Clin Oncol. 2017 Jul 10;35(20):2251-2259
pubmed: 28489509
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Clin Chem. 2017 Mar;63(3):691-699
pubmed: 28073896
Oncotarget. 2016 Sep 13;7(37):60712-60722
pubmed: 27474173
BMC Cancer. 2018 Nov 19;18(1):1136
pubmed: 30453899
Cancer Cell. 2019 Mar 18;35(3):428-440.e5
pubmed: 30853353
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Clin Cancer Res. 2014 Mar 15;20(6):1698-1705
pubmed: 24429876
J Thorac Oncol. 2017 Jul;12(7):e92-e93
pubmed: 28629545
PLoS One. 2017 May 4;12(5):e0175779
pubmed: 28472036
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
BMC Cancer. 2016 Aug 11;16:622
pubmed: 27515171
J Mol Diagn. 2014 Sep;16(5):541-549
pubmed: 25017478
Semin Oncol. 2003 Jun;30(3):338-48
pubmed: 12870135
Br J Cancer. 2002 May 6;86(9):1367-72
pubmed: 11986765
PLoS One. 2015 Nov 05;10(11):e0141763
pubmed: 26540293
Chest. 2013 May;143(5 Suppl):e437S-e454S
pubmed: 23649451
J Clin Oncol. 2008 Aug 20;26(24):3950-7
pubmed: 18711184
Cancer Biomark. 2010;6(3-4):191-6
pubmed: 20660964
Oncotarget. 2017 Jun 14;8(32):52142-52155
pubmed: 28881720
Mol Cancer. 2018 Feb 26;17(1):67
pubmed: 29482551
NPJ Breast Cancer. 2017 Jul 3;3:24
pubmed: 28685160